About the Authors
- Elena Gaberman
-
Affiliation Sharett Institute of Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
- Lena Pinzur
-
Affiliation Pluristem Therapeutics Inc., Haifa, Israel
- Lilia Levdansky
-
Affiliation Sharett Institute of Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
- Maria Tsirlin
-
Affiliation Sharett Institute of Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
- Nir Netzer
-
Affiliation Pluristem Therapeutics Inc., Haifa, Israel
- Zami Aberman
-
Affiliation Pluristem Therapeutics Inc., Haifa, Israel
- Raphael Gorodetsky
-
* E-mail: rafi@hadassah.org.il
Affiliation Sharett Institute of Oncology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel
Competing Interests
Major parts of the research project were sponsored and performed in collaboration with Pluristem Therapeutics which also prepared and supplies the relevant cells on which the study is based. Authors Lena Pinzur, Nir Netzer and Zami Aberman were employed by Pluristem Therapeutics Inc. at the time of this project was performed. Pluristem Therapeutics Inc. has filed the following patent application which relate to the current study (Patent application Publication US2011/0293583 A1 and PCT/1B2012/000664)). They may have previous patents on similar other cell types which were not used in the current study. Pluristem Therapeutics Inc. does not market yet products relating to the relevant study (PLX-RAD). By the terms of the research contract. The authors and their institutes have no direct or indirect benefits from current or future patent applied by the company. The authors adhere to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: RG LP NN EG LL. Performed the experiments: RG EG LL LP MT. Analyzed the data: RG EG LL. Contributed reagents/materials/analysis tools: LL NN LP RG ZA. Wrote the paper: RG LL.